Kwas traneksamowy dla lepszego gojenia się po operacji mastoidectomii u pacjentów z przewlekłym zapaleniem ucha
Tranexamic Acid for Recovery After Modified Radical Mastoidectomy in Patients With Chronic Suppurative Otitis Media
W skrócie
Badanie sprawdza, czy zastosowanie leku zwanego kwasem traneksamowym przed operacją zmniejsza powikłania po zabiegu usunięcia wyrostka ssocorro ucha. Pacjenci z przewlekłym zapaleniem ucha zostają podzieleni na dwie grupy - jedną otrzymującą lek, drugą placebo - i obserwuje się u nich gojenie się ucha, poprawę słuchu oraz bezpieczeństwo leku. Badanie ma na celu znaleźć sposób na szybsze i lepsze wyleczenie pacjentów po tej operacji.
Oryginalny opis (angielski)
The main objective of this project is to conduct a multicentre, prospective, randomised, controlled clinical trial to evaluate the clinical value of tranexamic acid in patients undergoing mastoidectomy. The study population consists of patients with chronic suppurative otitis media scheduled to undergo mastoidectomy. They will be randomised in a 1:1 ratio to either the pre-operative intravenous tranexamic acid group or the saline control group; both groups will undergo treatment in accordance with standardised anaesthesia and surgical protocols. The main research components include:
1. Evaluation of the dry ear rate: The primary outcome measure was to compare the difference in dry ear rates between the two groups one month post-operatively, in order to verify the effect of tranexamic acid on improving the dry ear rate following mastoidectomy. The assessment of the dry ear rate was carried out by an ENT specialist unaware of the study group allocation via clinical otoscopic examination; a dry ear was defined as the absence of discharge in the ear canal and complete epithelialisation of the mastoid surgical site. The assessment time point for the primary outcome measure was one month post-operatively.
2. Postoperative hearing assessment: This will be assessed based on the improvement in hearing at 3 months postoperatively compared with preoperative levels.
3. Safety assessment: The safety assessment will primarily include common adverse reactions associated with the use of tranexamic acid (e.g. nausea, vomiting, dizziness) and serious adverse events (e.g. venous thromboembolism, myocardial infarction, epileptic seizures). These will be comprehensively evaluated in conjunction with clinical signs and laboratory tests to ensure the safety and feasibility of the intervention.
Through this study, the project aims to determine whether tranexamic acid can effectively reduce the incidence of dry ear in the early postoperative period following mastoidectomy, and to provide evidence-based support for its clinical implementation.